Business Wire

Aircall Acquires Vogent to Advance Its AI Voice Agent Built Natively into Business Phones

6.5.2026 12:03:00 CEST | Business Wire | Press Release

Share

Aircall, the AI-powered customer communications platform trusted by more than 22,000 businesses worldwide, today announced the acquisition of Vogent, an AI voice agent company. The acquisition adds a new layer of specialized voice AI technology to Aircall’s platform – strengthening the technology behind Aircall’s AI Voice Agent and moving it from already great to best-in-class.

While AI agents' chat or email based communication channels have exploded in popularity, voice is its own discipline – with unique demands around timing, interruption handling, call flows, and production reliability. Voice channel also comes with the highest expectations from customers, further putting scrutiny around the readiness of the technology. For many businesses deploying AI voice agents, the experience has not lived up to the hype.

With Vogent, Aircall enhances its AI Voice Agents with a deeper set of specialized AI technologies, including advanced speech models, more reliable turn-taking, and higher precision over how AI models behave in those live phone calls. Integrated with Aircall’s easy-to-use platform, growing businesses around the world can deploy voice agents without any specialized technical expertise while still having access to best-in-class voice agents that drive reliable outcomes – more reliable automation on repetitive calls, better customer qualification on inbound opportunities, stronger containment before escalation, and when necessary, seamless hand-off experience to their teams.

Vogent’s San Francisco-based team joins a company accelerating its presence across the US in major tech hubs of San Francisco, Seattle, and New York. Along with its deep European roots, Aircall AI is committed to providing best-in-class AI customer communication services to businesses globally.

“Aircall has always focused on helping teams have better conversations with customers. Our AI Voice Agent helps businesses automate high-volume interactions on the communications platform they trust for voice. With Vogent, we are taking the next step: deepening the AI stack behind that experience with more technology and expertise across voice activity detection, conversational flow routing, custom voice models, and continuous refinement. That is where voice AI becomes truly valuable – not when it is added as a feature by a generalist CX platform, but when it is built by a company that understands voice at its core.” — Scott Chancellor, CEO, Aircall

“At Vogent, we've had one focus: building the most advanced voice AI pipeline on the market. That means custom models throughout the stack, from the voices themselves to turn detection, interruption handling, and latency management, because those are the things that separate a demo from something you can trust on a real customer call. That focus has powered millions of dials for businesses across industries.” — Vignesh Varadarajan, CTO, Vogent

“When we started talking to Aircall, the fit was clear. They had already built a strong AI Voice Agent on top of a platform trusted by 22,000 businesses, and bringing our technology and customers to that platform means the pipeline we've spent years refining can now reach businesses at a scale we couldn't have built toward alone.” — Jagath Vytheeswaran, CEO, Vogent

About Aircall

Aircall is an AI-powered customer communications platform for sales and support teams. The platform helps more than 22,000 businesses collaboratively manage voice, SMS, and WhatsApp conversations, handle high-volume inbound interactions autonomously through AI Voice Agent, automate post-call workflows, and connect every interaction to the tools they already use across 250+ native integrations. Founded in Paris, Aircall serves customer-facing teams globally.

About Vogent

Vogent is an AI voice agent company focused on the core layers that make automated phone conversations work in production. Its platform is designed to help businesses build, test, deploy, maintain, and refine voice AI agents with more natural conversation flow, deeper customization, and stronger operational performance.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260506396746/en/

Contacts

Coltin Kinsey
coltin.kinsey@aircall.io

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye